文献速递淋巴瘤

Mogamulizumab治疗成人T细胞白血病-淋巴瘤的多中心前瞻性观察研究

Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study.
PubMed 文献 · Blood Adv · 2020-01-01

MIMOGA研究纳入102例未接受过Mogamulizumab的ATL患者,101例接受含Mogamulizumab治疗。总体缓解率65%,中位无进展生存期7.4个月,中位总生存期16.0个月。治疗前Tax特异性CTL比例较高与生存期延长显著相关,而CMV特异性CTL无此关联。

要点

  • Mogamulizumab在ATL中显示临床有意义的抗肿瘤活性,ORR 65%,mPFS 7.4个月,mOS 16.0个月。
  • 治疗前较高Tax特异性CTL比例与更长生存显著相关,CMV特异性CTL无此关联。
  • 急性型或淋巴瘤型、较高sIL-2R水平、较低CD2-CD19+ B细胞比例为OS独立不良预后因素。

核心结论

  • Mogamulizumab在ATL中发挥临床有意义的抗肿瘤活性。
  • 患者接受Mogamulizumab前的免疫状态与治疗结局显著相关。

研究设计与样本

  • 多中心前瞻性观察研究(MIMOGA,UMIN000008696)。
  • 纳入未接受过Mogamulizumab的ATL患者102例,其中101例接受含Mogamulizumab治疗(急性型68例、淋巴瘤型18例、慢性型12例、冒烟型3例)。

主要发现

  • 总体缓解率为65%,中位无进展生存期7.4个月,中位总生存期16.0个月。
  • 入组时血清sIL-2R水平与全淋巴细胞或CD8+ T细胞亚群中Tax特异性CTL百分比呈显著负相关,与CMV pp65特异性CTL无相关性。
  • 全淋巴细胞或CD8+ T细胞亚群中较高Tax特异性CTL百分比与更长生存显著相关,CMV特异性CTL无此关联。
  • 多因素分析确定临床亚型(急性型或淋巴瘤型)、较高sIL-2R水平、外周血单个核细胞中较低CD2-CD19+ B细胞百分比为OS的显著独立不良预后因素。

临床怎么用

  • 治疗前评估Tax特异性CTL比例、sIL-2R水平、B细胞比例及临床亚型有助于判断Mogamulizumab治疗预后。

局限性

  • 需进一步开展时间序列免疫分析及全面基因组分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monitoring of Immune Responses Following Mogamulizumab-Containing Treatment in Patients with Adult T-Cell Leukemia-Lymphoma (ATL) (MIMOGA) is a multicenter prospective observational study to establish the most effective and safe treatment strategy using mogamulizumab for ATL patients (UMIN000008696). Mogamulizumab-naive patients were enrolled (n = 102), of whom 101 received mogamulizumab-containing treatment (68 acute, 18 lymphoma, 12 chronic, and 3 smoldering subtypes). At enrollment, there was a significant inverse correlation between serum soluble interleukin-2 receptor (sIL-2R) levels and percentages of Tax-specific cytotoxic T lymphocytes (Tax-CTLs) in the entire lymphocyte population or in the CD8+ T cell subset, but there was not a correlation with cytomegalovirus pp65-specific cytotoxic T lymphocytes (CMV-CTLs). The overall response rate was 65%, and median progression-free survival and overall survival (OS) were 7.4 and 16.0 months, respectively. A higher percentage of Tax-CTLs, but not CMV-CTLs, within the entire lymphocyte population or in the CD8+ T cell subset was significantly associated with longer survival. Multivariate analysis identified the clinical subtype (acute or lymphoma type), a higher sIL-2R level, and a lower percentage of CD2-CD19+ B cells in peripheral blood mononuclear cells as significant independent unfavorable prognostic factors for OS. This indicates that a higher percentage of B cells might reflect some aspect of a favorable immune status leading to a good outcome with mogamulizumab treatment. In conclusion, the MIMOGA study has demonstrated that mogamulizumab exerts clinically meaningful antitumor activity in ATL. The patient's immunological status before mogamulizumab was significantly associated with treatment outcome. Further time series immunological analyses, in addition to comprehensive genomic analyses, are warranted.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yonekura K, Kusumoto S, Choi I, et al. Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study. Blood Adv. 2020. PMID: 33091125. doi:10.1182/bloodadvances.2020003053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。